Login to Your Account

Cell Medica pads coffers with $74M series C for T-cell immunotherapies

By Nuala Moran
Staff Writer

Thursday, March 16, 2017

LONDON – Cell Medica Ltd. has raised £60 million (US$74.1 million) in a series C round to fund the parallel development of four second-generation T-cell cancer immunotherapy programs targeted at solid tumors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription